Experience with a new hypoglycemic agent, glibenclamide, HB 419 (Daonil) in diabetes mellitus.
D001835:Body Weight; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004357:Drug Synergism; D005905:Glyburide / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000097:blood / Q000627:therapeutic use; D007330:Insulin Antibodies / Q000097:blood; D009325:Nausea / Q000139:chemically induced; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D014581:Urticaria / Q000139:chemically induced
D007328:Insulin; D007330:Insulin Antibodies; D013453:Sulfonylurea Compounds; D005905:Glyburide